Prognostic value of claudin 18.2 expression in gastric adenocarcinoma

Table 1 Clinicopathological characteristics of patients with gastric adenocarcinoma based on claudin 18.2 expression

Parameter	Number of cases		CLDN18.2 score								P value
			0		1		2		3
	n	%	n	%	n	%	n	%	n	%
Age in yr
< 65	30	46.2	4	13.3	10	33.3	9	30.0	7	23.3	0.091
≥ 65	35	53.8	13	37.1	10	28.6	5	14.3	7	20.0
Sex
Male	49	75.4	14	28.6	15	30.6	11	22.4	9	18.4	0.314
Female	16	24.6	3	18.8	5	31.3	3	18.8	5	31.3
Lauren classification
Intestinal	41	63.1	9	22.0	12	29.3	10	24.4	10	24.4	0.221
Diffuse	24	39.9	8	33.3	8	33.3	4	16.7	4	16.7
Tumor grade
G1	30	46.2	9	30.0	8	26.7	7	23.3	6	20.0	0.889
G2	8	12.3	1	12.5	3	37.5	2	25.0	2	25.0
G3	27	41.5	7	25.9	9	33.3	5	18.5	6	22.2
Localization
Cardia	18	27.7	3	16.7	9	50.0	3	16.0	3	16.7	0.307
Corpus	10	18.5	4	33.3	5	41.7	1	8.3	2	16.7
Antrum	12	15.4	3	30.0	3	30.0	2	20.0	2	20.0
Pylorus	2	2.1	0	0.0	0	0.0	2	100.0	0	0.0
Antropyloric	23	35.4	7	30.4	3	13.0	6	26.1	7	30.4
Her2Neu
Negative	54	83.1	13	24.1	15	27.8	13	24.1	13	24.1	0.116
Positive	11	16.9	4	36.4	5	45.5	1	9.1	1	9.1
Family history
No	40	61.5	13	32.5	9	22.5	10	25.0	8	20.0	0.751
Yes	14	21.5	2	14.3	6	42.9	2	14.3	4	28.6
Unknown	11	16.9	2	18.2	5	45.5	2	18.2	2	18.2
Liver metastasis
No	33	50.8	8	25.0	10	31.3	6	18.8	8	25.00	0.703
Yes	32	49.2	9	27.3	10	30.3	8	24.2	6	18.2
Lung metastasis
No	48	73.2	9	52.9	3	17.6	2	11.8	3	17.6	0.053
Yes	17	26.8	8	16.7	17	35.4	12	25.0	11	22.9
Metastasis sites
Liver	16	24.6	2	12.5	7	43.8	2	12.5	5	31.3	0.050
Lung	4	6.2	2	50.0	0	0.0	0	0.0	2	50.0
Peritoneum	11	16.9	0	0.0	5	45.5	3	27.3	3	27.3
LAP	14	21.5	4	28.6	2	14.3	6	42.90	2	14.30
Brain	2	3.1	2	100.0	0	0.0	0	0.0	0	0.0
Liver + lung	17	26.2	7	41.2	6	35.0	2	11.8	2	11.8
Ovary	1	1.5	0	0.0	0	0.0	1	100.0	0	0.0
Adjuvant chemotherapy
No	29	44.6	8	27.6	9	31.0	6	20.7	6	20.7	0.793
Yes	36	55.4	9	25.0	11	30.6	8	22.2	8	22.2
Neoadjuvant chemotherapy
No	61	91.8	14	23.0	20	32.8	13	21.3	14	23.0	0.097
Yes	4	8.2	3	75.0	0	0.0	1	25.0	0	0.0
Exitus
No	7	10.8	0	0.0	3	42.9	3	42.9	1	14.3	0.401
Yes	58	89.2	17	29.3	17	29.3	11	19.0	13	22.4

CLDN18.2: Claudin 18.2; LAP: Lymphadenopathy.

Table 2 Univariate and multivariate analysis of baseline characteristics for progression-free survival

Parameter	Progression-free survival univariate analysis				Progression-free survival multivariate analysis
	HR	95%CI	P		HR	95%CI	P
Age in yr	1.36	0.80-2.30	0.26	Age in yr	1.29	0.71-2.33	0.41
Sex	1.40	0.76-2.56	0.28	Sex	1.49	0.73-3.05	0.28
Lauren classification	0.89	0.52-1.53	0.67	Lauren classification	0.93	0.39-2.22	0.87
Tumor grade	0.85	0.49-1.47	0.56	Tumor grade	0.91	0.58-1.43	0.69
Family history	0.87	0.45-1.77	0.75	Family history	0.51	0.20-1.28	0.15
Liver metastasis	1.09	0.64-1.85	0.75	Liver metastasis	1.07	0.60-1.91	0.82
Lung metastasis	0.93	0.52-1.66	0.79	Lung metastasis	0.98	0.49-1.94	0.95
Localization	0.94	0.42-2.11	0.88	Localization	1.01	0.81-1.24	0.98
Metastasis sites	0.83	0.27-2.60	0.75	Metastasis sites	0.99	0.84-1.18	0.94
Her2Neu	0.81	0.40-1.64	0.56	Her2Neu	0.85	0.37-1.93	0.69
CLDN18.2	1.22	0.54-2.32	0.77	CLDN18.2	1.30	0.54-3.19	0.56

CI: Confidence interval; CLDN18.2: Claudin 18.2; HR: Hazard ratio.

Table 3 Univariate and multivariate analysis of baseline characteristics for overall survival

Paragraph	Overall survival univariate analysis			Overall survival multivariate analysis
	HR	95%CI	P		HR	95%CI	P
Age in yr	2.46	1.39-4.33	0.01	Age in yr	3.17	1.45-6.92	0.01
Sex	1.10	0.61-1.99	0.75	Sex	0.65	0.26-1.59	0.34
Lauren classification	1.28	0.66-1.94	0.66	Lauren classification	1.23	0.24-6.16	0.81
Tumor grade	0.41	0.15-1.07	0.07	Tumor grade	0.29	0.08-1.06	0.06
Family history	0.83	0.36-1.97	0.67	Family history	2.14	0.68-6.71	0.19
Liver metastasis	0.94	0.56-1.59	0.82	Liver metastasis	0.74	0.33-1.65	0.46
Lung metastasis	0.71	0.39-1.27	0.25	Lung metastasis	0.58	0.22-1.52	0.27
Localization	0.91	0.46-1.79	0.78	Localization	2.14	0.68-6.71	0.19
Metastasis sites	1.36	0.30-6.09	0.69	Metastasis sites	1.88	0.52-6.82	0.34
Her2Neu	1.11	0.56-2.22	0.77	Her2Neu	0.90	0.35-2.34	0.83
CLDN18.2	1.68	0.81-3.50	0.12	CLDN18.2	2.78	0.85-9.07	0.09

CI: Confidence interval; CLDN18.2: Claudin 18.2; HR: Hazard ratio.